Published in Br J Pharmacol on March 17, 2015
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov (2009) 6.69
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol (2013) 5.74
G protein-coupled receptor allosterism and complexing. Pharmacol Rev (2002) 5.01
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev (2003) 2.93
Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov (2002) 2.85
Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49
Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry (2008) 2.47
Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature (1998) 1.84
Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol (1983) 1.73
Bi- or multifunctional opioid peptide drugs. Life Sci (2009) 1.69
New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology (1997) 1.61
Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends Pharmacol Sci (1996) 1.60
Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics. Biophys J (1995) 1.53
Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol (2006) 1.47
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol (2010) 1.41
High avidity scFv multimers; diabodies and triabodies. J Immunol Methods (1999) 1.32
Conformational adaptation in drug-target interactions and residence time. Future Med Chem (2011) 1.32
The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu Rev Pharmacol Toxicol (2011) 1.26
Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Mol Pharmacol (2006) 1.20
Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res (1992) 1.17
Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther (2009) 1.15
A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem (2011) 1.13
The pharmacology of salmeterol. Life Sci (1993) 1.13
Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol (2010) 1.07
Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci (2012) 1.04
In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther (2012) 1.03
Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J Biol Chem (2001) 1.03
On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. Mol Pharmacol (1998) 0.99
Structural basis of allosteric ligand-receptor interactions in the insulin/relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors. Ann N Y Acad Sci (2009) 0.98
Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol. Br J Pharmacol (2009) 0.97
Target-drug interactions: first principles and their application to drug discovery. Drug Discov Today (2011) 0.96
Quantifying the rebinding effect in multivalent chemical ligand-receptor systems. J Chem Phys (2012) 0.95
Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. Mol Pharmacol (2013) 0.93
A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol (2007) 0.92
Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol (2013) 0.92
Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur J Pharmacol (1999) 0.91
Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite. Mol Pharmacol (1996) 0.88
On the benefit of bivalency in peptide ligand/pin1 interactions. J Mol Biol (2007) 0.87
Application of receptor theory to allosteric modulation of receptors. Prog Mol Biol Transl Sci (2013) 0.87
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem Pharmacol (2001) 0.87
Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem Pharmacol (1999) 0.86
Allosteric modulators of class B G-protein-coupled receptors. Curr Neuropharmacol (2007) 0.85
On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol (2009) 0.85
Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model. Brain Res (1980) 0.85
Effects of the geometry of the immunological synapse on the delivery of effector molecules. Biophys J (2004) 0.84
Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.84
A thermodynamic approach to problems of drug antagonism I. The "Charnière theory". Eur J Pharmacol (1969) 0.83
Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems. Expert Opin Drug Discov (2012) 0.82
Bitopic ligands: all-in-one orthosteric and allosteric. F1000 Biol Rep (2009) 0.80
[3H]diprenorphine receptor binding in vivo and in vitro. Eur J Pharmacol (1982) 0.79
The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor. Pulm Pharmacol Ther (2010) 0.78
Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting. J Am Chem Soc (2013) 0.77
A pharmacological study of the angiotensin receptor and tachyphylaxis in smooth muscle. Gen Pharmacol (1976) 0.77
Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev (2007) 6.00
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis (2003) 4.49
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med (2004) 4.39
Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics (2009) 3.00
Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins. Mol Pharmacol (2010) 1.91
μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol (2010) 1.83
A review of standards for data exchange within systems biology. Proteomics (2007) 1.61
Nucleotide polymorphism and phenotypic associations within and around the phytochrome B2 Locus in European aspen (Populus tremula, Salicaceae). Genetics (2008) 1.61
In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther (2006) 1.42
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol (2010) 1.41
Early onset severe pre-eclampsia: expectant management at a secondary hospital in close association with a tertiary institution. BJOG (2005) 1.39
Assessing the minimum number of data points required for accurate IC50 determination. Assay Drug Dev Technol (2005) 1.35
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS (2011) 1.23
Automated reconstruction of ancient languages using probabilistic models of sound change. Proc Natl Acad Sci U S A (2013) 1.23
Clinal variation in phyB2, a candidate gene for day-length-induced growth cessation and bud set, across a latitudinal gradient in European aspen (Populus tremula). Genetics (2005) 1.19
Leaving paediatrics: the experience of service transition for young disabled people and their family carers. Health Soc Care Community (1998) 1.18
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol (2006) 1.17
Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol (2009) 1.16
The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A (2010) 1.15
M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. Proc Natl Acad Sci U S A (2010) 1.15
Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol (2010) 1.14
Molecular evolution and emergence of avian gammacoronaviruses. Infect Genet Evol (2012) 1.13
Endomorphin-2: a biased agonist at the μ-opioid receptor. Mol Pharmacol (2012) 1.10
Further studies on sex pheromones of female Lygus and related bugs: development of effective lures and investigation of species-specificity. J Chem Ecol (2014) 1.07
Assessment of applicants to the veterinary curriculum using a multiple mini-interview method. J Vet Med Educ (2009) 1.04
Gene flow and selection on phenotypic plasticity in an island system of Rana temporaria. Evolution (2010) 1.04
Primary care for children in the 21st century. BMJ (2005) 1.02
Genetic differentiation, clinal variation and phenotypic associations with growth cessation across the Populus tremula photoperiodic pathway. Genetics (2010) 1.00
Heat treatment eliminates 'Candidatus Liberibacter asiaticus' from infected citrus trees under controlled conditions. Phytopathology (2013) 0.98
Specific exercises to treat pregnancy-related low back pain in a South African population. Int J Gynaecol Obstet (2011) 0.94
The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther (2012) 0.94
Children's health and development: approaches to early identification and intervention. Arch Dis Child (2013) 0.93
Child protection--lessons from Victoria Climbié. BMJ (2003) 0.92
Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. Br J Pharmacol (2013) 0.92
Defects in tongue papillae and taste sensation indicate a problem with neurotrophic support in various neurological diseases. Neuroscientist (2008) 0.92
Time between skin incision and delivery during cesarean. Int J Gynaecol Obstet (2013) 0.91
The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol (2009) 0.91
Miniaturized receptor binding assays: complications arising from ligand depletion. J Biomol Screen (2007) 0.90
Safeguarding children: a call to action. Lancet (2008) 0.88
Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.88
Analysis of multiple histamine H₄ receptor compound classes uncovers Gαi protein- and β-arrestin2-biased ligands. Mol Pharmacol (2012) 0.87
A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy. PLoS One (2012) 0.86
Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists. Br J Pharmacol (2012) 0.86
Qualification discrepancies between urban and rural emergency department physicians. J Emerg Med (2005) 0.86
Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet Genomics (2011) 0.86
Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. S Afr Med J (2011) 0.85
Mortality after discharge from long-term psychiatric care in Scotland, 1977-94: a retrospective cohort study. BMC Public Health (2003) 0.85
Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing "micro-pharmacokinetic/pharmacodynamic relationships" at the β2-adrenoceptor. Mol Pharmacol (2014) 0.85
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. J Med Chem (2010) 0.85
A single point mutation (N514Y) in the human M3 muscarinic acetylcholine receptor reveals differences in the properties of antagonists: evidence for differential inverse agonism. J Pharmacol Exp Ther (2006) 0.84
Enhancing magnetic resonance imaging tumor detection with fluorescence intensity and lifetime imaging. J Biomed Opt (2011) 0.84
Total perinatally related losses at Tygerberg Hospital - a comparison between 1986, 1993 and 2006. S Afr Med J (2010) 0.84
ATP priming of macrophage-derived chemokine responses in CHO cells expressing the CCR4 receptor. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.84
Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. BMC Pharmacol Toxicol (2013) 0.83
Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization. Br J Pharmacol (2014) 0.83
Contrasting signal transduction mechanisms in bacterial and eukaryotic gene transcription. FEMS Microbiol Lett (2006) 0.83
An initial evaluation of post-cardiopulmonary bypass acute kidney injury in swine. Eur J Cardiothorac Surg (2009) 0.82
Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes. AIDS Res Hum Retroviruses (2012) 0.80
The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol (2013) 0.80
Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin Vaccine Immunol (2013) 0.80
Cardiac biomarkers at high altitude. High Alt Med Biol (2014) 0.80
The effects of high altitude on choice reaction time mean and intra-individual variability: Results of the Edinburgh Altitude Research Expedition of 2008. Neuropsychology (2010) 0.79
Spontaneous spinal epidural hematoma: a case report and literature review. J Emerg Med (2009) 0.79
A homogeneous high throughput nonradioactive method for measurement of functional activity of Gs-coupled receptors in membranes. J Biomol Screen (2002) 0.79
The in vitro metabolism of sphingosine-1-phosphate: identification; inhibition and pharmacological implications. Eur J Pharmacol (2011) 0.78
Non-elective Caesarean section: how long do we take to deliver? J Trop Pediatr (2005) 0.78
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. Bioorg Med Chem Lett (2012) 0.78
Assembly and targeting of liposomal nanoparticles encapsulating quantum dots. Bioconjug Chem (2011) 0.78
Can a new paediatric sub-specialty improve child health in South Africa? S Afr Med J (2012) 0.78
Synthesis and evaluation of two series of 4'-aza-carbocyclic nucleosides as adenosine A2A receptor agonists. Bioorg Med Chem Lett (2009) 0.78
Hypertension in pregnancy. Cardiovasc J S Afr (2002) 0.78
PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation. Biochem Biophys Res Commun (2002) 0.77
A mouse model for studying rapid intraoperative methods of skin closure and wound healing. Med Sci Monit (2003) 0.77
Paediatric out-of-hospital cardiac arrests in Melbourne, Australia: improved reporting by adding coronial data to a cardiac arrest registry. Emerg Med J (2012) 0.77
A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. Bioorg Med Chem Lett (2010) 0.77
HDL-like discs for assaying membrane proteins in drug discovery. Biophys Chem (2012) 0.76
BJP issue on drug discovery. Br J Pharmacol (2010) 0.75
Death risk other than from suicide is raised in self harm. BMJ (2003) 0.75
Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo. Br J Clin Pharmacol (2016) 0.75
Quality of life in children with cerebral palsy. Lancet (2007) 0.75
Role of a paediatric nurse in primary care 2: research findings. Br J Nurs (2003) 0.75
Increasing HIV treatment optimism but no changes in HIV risk behaviour among men who have sex with men (MSM) in Vancouver, Canada. J Acquir Immune Defic Syndr (2017) 0.75
Reviewing research involving children: the practice of British research ethics committees. IRB (1988) 0.75
The MRCPCH MasterCourse. Arch Dis Child (2008) 0.75
(2S,8Z)-2-butyroxy-8-heptadecene: major component of the sex pheromone of chrysanthemum gall midge, Rhopalomyia longicauda. J Chem Ecol (2009) 0.75
Integrated 1550 nm photoreceiver with built-in amplification and feedback mechanisms. Opt Lett (2013) 0.75
An asymmetric synthesis of aza analogues of the tricyclic skeleton of daphnane and the ABC ring system of phorbol. J Org Chem (2003) 0.75
Peripherally administered growth hormone increases brain dopaminergic activity and swimming in rainbow trout. Horm Behav (2004) 0.75
Are affluent, well-educated, career-orientated women knowledgeable users of the oral contraceptive pill? J Fam Plann Reprod Health Care (2005) 0.75
Measuring receptor target coverage: a radioligand competition binding protocol for assessing the association and dissociation rates of unlabeled compounds. Curr Protoc Pharmacol (2010) 0.75
The development of One Health approaches in the Western Pacific. Curr Top Microbiol Immunol (2013) 0.75
Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D Receptor. J Med Chem (2019) 0.75
Role of a paediatric nurse in primary care 1: research issues. Br J Nurs (2003) 0.75
Enabling women to breast feed. BMJ (2008) 0.75
The impact of specialist experience in the surgical management of perianal abscesses. Int J Surg (2011) 0.75
Complementary metal-oxide-semiconductor compatible 1060 nm photodetector with ultrahigh gain under low bias. Opt Lett (2015) 0.75